How much cash does Revolution Medicines, Inc. generate?

Revolution Medicines, Inc. (RVMD) generated -$1.1B in operating cash flow over the trailing twelve months.

What is Revolution Medicines, Inc.'s free cash flow?

After $14.3M of capital expenditures, Revolution Medicines, Inc.'s free cash flow was -$1.1B over the trailing twelve months, down 78.1% year over year.

Where does Revolution Medicines, Inc.'s cash flow data come from?

Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.

Revolution Medicines, Inc. RVMD Cash Flow Statement

Income Statement Balance Sheet Cash Flow Ratios Segments

Quarterly Annual TTM

YoY QoQ

Simplified Detailed

	Q1 '26	Q4 '25	Q3 '25	Q2 '25	Q1 '25
Net income	-$453.82M-24.4%	-$364.89M-19.6%	-$305.21M-23.2%	-$247.79M-16.1%	-$213.42M-9.7%
Depreciation and amortization	$2.35M+3.5%	$2.27M+9.9%	$2.06M+17.3%	$1.76M+3.9%	$1.69M-2.5%
Stock-based compensation	$87.3M+159%	$33.7M+9.5%	$30.78M+6.8%	$28.83M+14.9%	$25.08M+11.8%
Impairment charges	——	——	$0—	$0—	$0—
Change in accounts receivable	——	$0—	$0—	$0—	$0—
Change in accounts payable	$16.86M—	——	$19.55M+123%	$8.76M+206%	-$8.27M—
Change in accrued liabilities	-$16.74M-131%	$54.6M+20.6%	$45.29M+319%	$10.82M+599%	$1.55M-91.5%
Change in other assets	$10.47M+6,699%	$154K—	——	$17.27M+2,358%	-$765K+69.3%
Change in other liabilities	$5.66M—	——	——	$2.31M-33.5%	$3.47M—
Amortization of intangible assets	$0-100%	$69K-77.0%	$300K0.0%	$300K+12.4%	$267K0.0%
Non-cash operating lease expense	$2.19M-7.5%	$2.37M+17.8%	$2.01M+13.0%	$1.78M+1.1%	$1.76M+26.9%
Change in operating lease liabilities	-$2.07M—	——	——	-$1.56M-3.6%	-$1.5M—
Net cash from operating activities	-$354.17M-29.1%	-$274.24M-32.3%	-$207.31M+6.5%	-$221.76M-14.1%	-$194.44M-40.6%
Capital expenditures	$1.54M-20.1%	$1.93M-42.5%	$3.35M-55.0%	$7.45M+128%	$3.27M+167%
Net cash from investing activities	$172.62M+131%	$74.88M+201%	$24.85M-27.5%	$34.28M+315%	-$15.95M+95.9%
Proceeds from issuance of common stock	$12.21M+275%	-$6.97M-268%	$4.15M+114%	$1.94M+117%	$891K-99.9%
Taxes paid for net share settlement	——	$0—	$0—	$0—	$0—
Net cash from financing activities	$238.74M-34.7%	$365.66M—	$0-100%	$256.58M+29,257%	$874K-99.9%
Net increase (decrease) in cash	$57.19M—	——	-$184.05M—	——	-$209.51M—
Accretion (Amortization) of Discounts and Premiums, Investments	$3.22M-29.2%	$4.55M-20.3%	$5.72M-26.2%	$7.74M-21.1%	$9.82M+11.2%
Amortization of capitalized software and acquired intangible assets	$0-100%	$69K-77.0%	$300K0.0%	$300K+12.4%	$267K0.0%
Accrued expenses and other liabilities	-$16.74M-131%	$54.6M+20.6%	$45.29M+319%	$10.82M+599%	$1.55M-91.5%
Increase (Decrease) in Deposit Assets	$10.56M+44.7%	$7.3M—	——	——	-$565K-123%
Operating lease liabilities	-$2.07M—	——	——	-$1.56M-3.6%	-$1.5M—
Other long-term liabilities	$5.66M—	——	——	$2.31M-33.5%	$3.47M—
Increase Decrease In Other Prepaid And Noncurrent Assets	$378K—	——	——	——	$200K—
Increase (Decrease) in Prepaid Expense and Other Assets	$10.47M+210%	$3.38M-36.9%	$5.36M-27.3%	$7.36M+215%	-$6.43M-226%
Operating lease right-of-use asset amortization	$2.19M-7.5%	$2.37M+17.8%	$2.01M+13.0%	$1.78M+1.1%	$1.76M+26.9%
Payment-in-kind interest	$12.2M+2.2%	$11.94M+4.5%	$11.43M+1,220%	$866K—	$0—
Cash And Cash Equivalents And Restricted Cash Acquired In Connection With Eqrx Acquisition Net Of Transaction Costs	——	$0—	$0—	$0—	$0—
Payments Of Deferred Offering Costs	$252K+232%	-$191K-324%	-$45K-2,150%	-$2K-111%	$18K+106%
Proceeds From Issuance Of Common Stock From At The Market Offering	$226.73M-34.8%	$347.92M—	——	——	$0-100%
Proceeds from issuance of common stock relating to employee stock plans	$12.21M—	——	$4.15M+114%	$1.94M+117%	$891K-78.7%
Proceeds From Warrant Exercises	$57K—	——	$3K—	——	$1K—
Accrued payables for capital expenditures	$786K+73.1%	$454K—	——	$122K-95.6%	$2.79M+190%
Fair Value Of Net Assets Acquired In Connection With Eqrx Acquisition	——	$0—	$0—	$0—	$0—
Issuance Of Common Stock For Eqrx Acquisition Net Of Shares Withheld For Taxes	——	$0—	$0—	$0—	$0—
Proceeds From Issuance Of Warrants	——	$0—	$0—	$0—	$0-100%
Free cash flow	-$355.7M-28.8%	-$276.16M-31.1%	-$210.66M+8.1%	-$229.21M-15.9%	-$197.7M-41.7%
Free cash flow	-$355.7M-28.8%	-$276.16M-31.1%	-$210.66M+8.1%	-$229.21M-15.9%	-$197.7M-41.7%

Chart any of these lines over time, or line them up against competitors.

Compare these in charts →

Questions, answered.

How much cash does Revolution Medicines, Inc. generate?: Revolution Medicines, Inc. (RVMD) generated -$1.1B in operating cash flow over the trailing twelve months.
What is Revolution Medicines, Inc.'s free cash flow?: After $14.3M of capital expenditures, Revolution Medicines, Inc.'s free cash flow was -$1.1B over the trailing twelve months, down 78.1% year over year.
Where does Revolution Medicines, Inc.'s cash flow data come from?: Every line is extracted from Revolution Medicines, Inc.'s SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.